Jill Howe is the Chief Financial Officer for Lineage Cell Therapeutics and also serves on the Board of Directors for Codagenix and the MUSC Foundation. She has more than 20 years of experience in the biotechnology sector in operational and financial strategy, treasury, global infrastructure, and compliance management. Most recently, Ms. Howe was CFO of DTx Pharma, and prior to that, she served as Treasurer and Vice President of Finance for Gossamer Bio, a clinical-stage biopharmaceutical company, where she was the internal project lead for the company’s initial public offering, follow-on, and debt offerings, and oversaw finance for 18 subsidiaries across the U.S. and Ireland. She previously held Controller and Director of Finance roles at Amplyx Pharmaceuticals, which was subsequently acquired by Pfizer, at Receptos, Inc., which was acquired by Celgene, and at Somaxon Pharmaceuticals, which was acquired by Pernix. Ms. Howe received a Bachelor of Science in Accountancy from San Diego State University.